Markets

BioCardia Announces Completion Of Process With Japan's Pharmaceuticals And Medical Devices Agency Seeking Regulator Nod For Its CardiAMP Cell Therapy system To Treat Ischemic Heart Failure

Nov 6, 2026 · 08:35 AM ET· updated 1h ago

BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's

Why It Matters

BioCardia finished asking Japan's medicine regulators to approve its heart therapy. Watch to see if Japan says yes, which would help the company grow internationally.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BCDA0.91

+0.02 (+1.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.